Defense Spending Outlook Could Propel This Thrilling ETFAerospace and defense stocks have been displaying leadership for awhile now. They derive significant benefit from global governments pledging to allocate more capital to national security. Market participants following the industry know that for the better part of a year, it's felt as though every week a government pledges to ramp up defense spending.Related to that, research firms frequently issue accelerated defense spending forecasts, highlighting o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0063 Expires: December 31, 2026 Estimated average burden hours per response . . . 1,694.52 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe ...

Core Insights - Oppenheimer & Co. Inc. has appointed Vien Le as Managing Director in its Public Finance Investment Banking Group, based in Los Angeles [1][2] - Le brings over 20 years of municipal finance experience, focusing on California and supporting clients in the West, including Oregon and Washington [2][3] - The addition of Le is expected to enhance Oppenheimer's capabilities and momentum in the public finance sector on the West Coast [3][5] Company Overview - Oppenheimer Holdings Inc. provides a comprehensive range of wealth management, securities brokerage, and investment banking services to high-net-worth individuals, families, corporate executives, businesses, and institutions [5]

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at Oppenheimer 36th Annual Healthcare Life Sciences Conference which is being held virtually. The presentation will be on Thursday, February 26, 2026 at 2:40pm ET. A webcast of the presentation will be available live and for 90 ...

Core Insights - Oppenheimer analysts have conducted positive channel checks for CrowdStrike and SentinelOne, indicating strong performance in the cybersecurity sector [1][2]. CrowdStrike - CrowdStrike remains a leader in next-generation endpoint security, with accelerating revenue growth in fiscal 2026 following a significant IT outage in summer 2024 [4]. - The company has received the best sentiment from VAR partners, who have revised their expectations positively, highlighting CrowdStrike's success in replacing legacy vendors and effective cross-selling [5]. - The introduction of the Falcon Flex licensing model has been a key driver of success, allowing customers to access the full product portfolio while only paying for needed modules [7]. - CrowdStrike's stock is trading at a forward price-to-sales (P/S) multiple of approximately 18 times analysts' estimates for the next fiscal year [8]. SentinelOne - SentinelOne is considered one of the cheapest endpoint security providers, trading at a forward P/E of below 4 times next fiscal year estimates, while experiencing rapid revenue growth with a 23% increase in both revenue and annualized recurring revenue (ARR) in fiscal Q3 [9]. - Oppenheimer's channel checks indicate significant improvements for SentinelOne, with most VARs exceeding their plans for 2025 and reporting high-20% growth for the calendar year [11]. - SentinelOne's Purple AI has been recognized as the best autonomous security operations center (SOC) solution, outperforming competitors like CrowdStrike's Charlotte AI [11]. - Given its strong technology and revenue growth, SentinelOne is viewed as one of the most underpriced stocks in the market, with potential for significant upside [12].

Core Insights - KKR & Co. Inc. has seen significant changes in institutional ownership, with several hedge funds increasing their positions dramatically in the third quarter of the year [1][6] - Insider trading activity indicates confidence in the company's future, with both the Director and CEO purchasing substantial shares [2] - Analysts have mixed but generally positive outlooks on KKR's stock, with upgrades and downgrades from various firms [3][4] Institutional Ownership - Covenant Asset Management LLC increased its holdings by 1,424.8%, now owning 29,826 shares valued at $3,876,000 after acquiring 27,870 shares [1] - Cumberland Partners Ltd raised its position by 816.2%, owning 25,791 shares worth $3,352,000 after acquiring 22,976 shares [1] - Allen Investment Management LLC increased its position by 165.0%, now holding 247,375 shares valued at $32,146,000 after acquiring 154,009 shares [1] - Stonegate Investment Group LLC purchased a new position valued at approximately $6,219,000 [1] - Generali Asset Management SPA SGR boosted its position by 132.5%, now owning 37,323 shares valued at $4,850,000 after purchasing 21,270 shares [1] - Institutional investors currently own 76.26% of KKR's stock [1] Insider Transactions - Director Matt Cohler acquired 43,872 shares at an average cost of $102.90 per share, totaling $4,514,428.80, representing a 2,733.46% increase in his position [2] - CEO Scott C. Nuttall purchased 125,000 shares at an average price of $102.66 per share, totaling $12,832,500, resulting in a 0.81% increase in his holdings [2] - Insiders have collectively bought 343,872 shares worth $35,367,179 over the last three months, with insiders owning 39.34% of the company's stock [2] Analyst Ratings - HSBC upgraded KKR from a "hold" to a "buy" rating with a price target of $144.00 [3] - Barclays lowered its price target from $159.00 to $136.00 while maintaining an "overweight" rating [3] - Wall Street Zen upgraded KKR from a "sell" to a "hold" rating [4] - Oppenheimer reduced its price target from $190.00 to $187.00, maintaining an "outperform" rating [4] - UBS Group lowered its target price from $168.00 to $125.00 while keeping a "buy" rating [4] - The average rating for KKR is "Moderate Buy" with an average target price of $153.50 [4] Financial Performance - KKR reported a quarterly EPS of $1.12, missing estimates of $1.14, with revenue of $5.93 billion, significantly exceeding expectations of $2.23 billion [7] - The company's quarterly revenue increased by 76.1% compared to the same quarter last year [7] - KKR's net margin stands at 11.97% and return on equity at 5.77% [7] Dividend Information - KKR announced a quarterly dividend of $0.185, with an annualized dividend of $0.74 and a yield of 0.7% [8] - The dividend payout ratio is currently 31.62% [8] Company Overview - KKR & Co. Inc. is a global investment firm specializing in private markets and alternative asset management, founded in 1976 [9] - The firm operates across various sectors including private equity, credit, real assets, growth equity, and hedge fund strategies [9][10]

Group 1 - The U.S. Supreme Court ruled that Trump's tariff policy lacked clear legal authority, leading to significant potential returns for hedge funds that had bet on this outcome [1][2] - Hedge funds and investment firms began acquiring theoretical refund rights from struggling importers at low prices as early as October last year, anticipating a favorable court ruling [1][4] - Investment company 117 Partners' founder, Thomas Braziel, invested $925,000 in refund claims and expects to see returns exceeding eight times his investment [1] Group 2 - Despite the Supreme Court ruling, the majority opinion did not address the issue of refunds, leaving uncertainty regarding the refund process to lower courts [2] - Legal experts suggest that the U.S. government may challenge any lower court rulings regarding refund claims, indicating a complex legal landscape ahead [2] - The estimated net customs revenue from increased tariffs is projected to reach $195 billion by fiscal year 2025, with Trump expressing concerns that refunding these funds could be detrimental to the country [2] Group 3 - Investment banks like Jefferies and Oppenheimer have been actively facilitating these unique transactions, matching importers with hedge funds seeking investment opportunities [4] - Hedge funds purchased refund rights at prices ranging from 20 to 40 cents on the dollar, with most transactions valued between $2 million and $200 million [4] - Oppenheimer's special assets team has engaged in over $1.6 billion of similar transactions related to tariffs since 2021, highlighting the growing interest in this niche market [4]

Core Insights - The company reported adjusted earnings per share of $0.45, an increase from $0.40 in the same quarter last year, indicating a potential stabilization in its retail business despite ongoing geopolitical challenges [1][34] - Consumer money transfer transactions decreased by 2.5% in the quarter, but cross-border principal growth showed resilience, suggesting a strong customer base adapting to macroeconomic conditions [2][37] - The company aims to build a digital-first, retail-enabled consumer services model, leveraging its global brand and payment capabilities to moderate fluctuations in its core remittance business [3][4] Financial Performance - For the fourth quarter, the company reported revenue of $1 billion, reflecting a 5% decline year-over-year on an adjusted basis [3][32] - The full year GAAP revenue was $4.1 billion, with adjusted revenue growth excluding Iraq down by 2% due to challenges in the Americas retail business [32][34] - Adjusted operating margin for the full year was 20%, up from 19% in the previous year, benefiting from cost discipline [34] Consumer Services and Digital Growth - Consumer services adjusted revenue grew by 26% in the fourth quarter and nearly 30% for the full year, driven by travel money and bill payments [35][36] - The branded digital business saw a 13% increase in transactions and a 6% rise in adjusted revenue, marking nine consecutive quarters of revenue growth [38][39] - The digital business now accounts for over 40% of the principal sent globally, with significant growth opportunities in the Middle East and other regions [21][22] Market Dynamics and Strategy - The company is focusing on operational efficiencies and expanding its payment capabilities to drive productivity and market competitiveness [4][6] - Recent geopolitical changes in regions like Chile and Venezuela are impacting migration and mobility, creating a dynamic environment for the business [8][62] - The implementation of a U.S. remittance tax has not materially impacted the business so far, but the company is closely monitoring its effects [9][15] Partnerships and Expansion - The company has secured several new exclusive partnerships, including with Canada Post and Deutsche Post, expected to generate at least $100 million in incremental retail revenue annually [27][29] - The company is expanding its wallet capabilities in various countries, including Australia, Mexico, Singapore, and the Philippines, to enhance customer retention and monetization [12][13][25] - The company is also developing a digital asset strategy, including the launch of a U.S. Dollar payment token and partnerships for stablecoin transactions [24][25][73] Outlook - The adjusted revenue outlook for 2026 is projected to grow by 6% to 9%, with adjusted EPS expected to be between $1.75 and $1.85 [44][45] - The company anticipates that the integration of Intermex will contribute positively to its financial performance, with expected synergies enhancing overall profitability [70][71] - The company is adapting its customer acquisition strategies to remain competitive in a changing market landscape, particularly in response to aggressive offers from lower-scale players [76][77]

Group 1 - Kiora Pharmaceuticals will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 3:20 p.m. ET, with a live webcast available on their investor relations website [1] - Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing advanced therapies for retinal diseases, utilizing innovative small molecules to address vision loss [2] - The company is developing KIO-104 for retinal inflammation and KIO-301 for retinitis pigmentosa, choroideremia, and Stargardt disease, with the latter being a molecular photoswitch aimed at restoring vision [2] Group 2 - Kiora Pharmaceuticals encourages investors to follow their updates on social media platforms like X and LinkedIn, as well as to visit their website for relevant information [3]

Core Viewpoint - Aldeyra Therapeutics, Inc. is focused on developing innovative therapies for immune-mediated diseases and will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [1] Company Participation - Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will engage in a virtual fireside chat at the conference [1] - The discussion will be moderated by Andreas Argyrides, Managing Director, Senior Biotech [1]